《艾昆纬:2023全球成人疫苗接种趋势报告-新冠疫情的影响(英文版)(11页).pdf》由会员分享,可在线阅读,更多相关《艾昆纬:2023全球成人疫苗接种趋势报告-新冠疫情的影响(英文版)(11页).pdf(11页珍藏版)》请在三个皮匠报告上搜索。
1、JULY?Trends in Global Adult Vaccination:Impact of COVID-19 RESEARCH BRIEFBackground?By 2030,the number of people aged 60 years and older is expected to increase by more than a third,to 1.4 billion.1?returns on investment at the individual,healthcare system,economic,societal and political levels.Howe
2、ver,despite?2 Maximizing the uptake of vaccines among the adult population is critical for reducing disease-associated outcomes and leads to improved health and reduced healthcare costs.3,4?at large,from both an economic and healthcare perspective.From an economic standpoint,VPDs result in a direct?
3、of productivity,increased absenteeism,and the need for caregiving.VPDs can also have a substantial adverse impact?In the European Union,VPDs cause an estimated 94,000 premature deaths annually6,7,8?of healthy life(62 disability-adjusted life years per 100,000 population).9,10 VPDs also increase the
4、risk of cardiovascular,cerebrovascular,neurological,and renal complications,adding to the burden from both an economic and healthcare perspective.Furthermore,the COVID-19 pandemic underscored the critical link between health and the economy,with more than$11 trillion USD in costs on response and$10
5、trillion in future lost earnings.11 It crucially exposed vulnerabilities within the older adult population.Simultaneously,the rapid development,implementation,and uptake of COVID-19 vaccines,resulting in over 72%of the worlds population receiving a dose,facilitated socioeconomic recovery and demonst
6、rated prevention can be prioritized if all stakeholders work together.Given this context,understanding the current status of adult vaccination in terms of uptake,as well as assessing the impact of COVID-19,is crucial for ensuring that appropriate policies,vaccine registries and protocol,and educatio
7、n campaigns are put in place to rebuild and improve coverage rates.This report aims to provide a baseline of adult vaccination trends and missed vaccination doses during the COVID-19 pandemic while assessing variations by countries and regions.2|Trends in Global Adult Vaccination:Impact of COVID-19G
8、lobal adult vaccines POSITIVE DEVELOPMENTS IN ADULT VACCINATION OVER THE PAST DECADE HAVE BEEN HINDERED BY?LOW UPTAKEOver the last decade,adult vaccines(in terms of volume?diphtheria,tetanus and pertussis(TDaP),hepatitis B,herpes zoster and pneumococcal have witnessed continual progress,reaching a p
9、eak of 400Mn doses in 2020 with historical CAGR(compound annual growth rate)of 7.9%between 2013 and 2019 and a CAGR of 8.9%,including 2020.This measurement of adult vaccine doses is based on IQVIA MIDAS data,which serves as a proxy for adult vaccination coverage as real time adult vaccine coverage d
10、ata is highly variable by country and oftentimes very limited.MIDAS provides a directional view on trends in vaccine coverage globally.While the progress in adult vaccination between 2013 and 2019 is commendable,overall levels of vaccine coverage for adults have still remained low,which suggests tha
11、t there is a need for further improvements.?Additionally,despite these developments in adult vaccination,the growth in vaccine doses associated with these diseases for the adult population has been adversely impacted by the COVID-19 pandemic.The overall doses for these vaccines reduced by 12%between
12、?represent 16.2 doses per 100 adults globally,which is in sharp contrast to the 132 COVID-19 vaccine doses received per 100 people by end of 2022 for the completion of the primary series,excluding boosters.16 Please note the COVID-19 vaccine doses per 100 people represents the entire population(incl
13、uding children),the doses per 100 adults is likely to be higher as the vaccination coverage rates in most countries was higher for adults.17?Source:IQVIA MIDAS?coverage for children and mothers).?of 1mL or larger were assumed for adult use.Includes retail and non-retail from 76 countries covered by
14、IQVIA MIDAS panels.These may not cover all vaccination delivery channels in each country.InfluenzaTd/TdaPHepatitis BHerpes zosterPneumococcal200002236347259285!54545302
15、0327530432234940035144+7.9%+8.9%iqviainstitute.org|3Estimated missed doses?The trends in vaccine doses for adults prior to the COVID-19 vaccination have been utilized to model the expected doses if the positive developments in vaccine uptake had continued.This modelling exercise provides two scenari
16、os(Exhibit 2):Scenario 1:This scenario uses the historical data trendline for the pre-pandemic period(2013-19).This period had a CAGR of 7.9%and extends the trendline up to 2022.The trendline smooths variations in the?and 2022 and actual doses is 24Mn doses in 2021 and?missed doses of adult vaccines
17、(TDaP,herpes zoster,?This scenario uses the historical data trend line for 2013 to 2020.This period had a CAGR of 8.9%and extends the trendline to 2022.The trendline smooths variations in the overall historical trend for the selected?trendline and actual doses is 41Mn doses in 2021 and 77Mn doses in
18、 2022,giving a total of 119Mn estimated missed doses of adult vaccines.The mid-point of these two scenarios gives an estimated 100Mn missed doses for the two years.?Source:IQVIA MIDAS?coverage for children and mothers).?of 1mL or larger were assumed for adult use.Scenario 1 and 2 are developed from
19、trendlines from 2013 to 2019 or 2020,respectively.Includes retail and non-retail from 76 countries covered by IQVIA MIDAS panels.These may not cover all vaccination delivery channels in each country.Actual202020212022Scenario 1Scenario 24003633580404428+119m+80mEstimated missed doses(2021
20、22):100Mn(Range:80Mn119Mn)4|Trends in Global Adult Vaccination:Impact of COVID-19WHILE IMMUNIZATION RATES FOR ADULT VACCINES?PANDEMIC HAD A DISPROPORTIONATELY NEGATIVE IMPACT ON ADULT VACCINE DOSES IN COUNTRIES THAT ARE IN THE MEDIUM OR LOW CATEGORY ON THE HUMAN DEVELOPMENT INDEX?are considered.The
21、Human Development Index(HDI)is a composite measure that considers life expectancy,education and per capita income.18 Countries at the top end of the HDI scale,“Very High”HDI,(e.g.USA,most of Europe,Japan and others),had been trending the most positively in vaccine volumes prior to the pandemic,?they
22、 saw a decline and are in the process of recovering.Despite this positive trend prior to the pandemic,it is important to note that all countries continue to have sub-optimal vaccine coverage rates for adults and that there is a need for attention toward increasing adult immunization globally.As exam
23、ples,TDaP and Herpes?these countries is between 41%and 60%.?“High”HDI countries(e.g.China,Mexico,Brazil)had experienced only a modest increase in adult vaccine volume in the 2000s,and after the pandemic,adult vaccination doses saw an increase,largely driven by?19,20 and have continued to remain abov
24、e the pre-pandemic trend.“Medium”level(e.g.India,Morocco,Philippines)and“Low”HDI countries(e.g.Pakistan,Senegal,Togo)witnessed substantial declines in adult vaccine volume and have not recovered with vaccination doses remaining well below the historic trendlines.?Source:IQVIA MIDAS?of 1mL or larger
25、were assumed for adult use.Includes retail and non-retail from 76 countries covered by IQVIA MIDAS panels.These may not cover all vaccination delivery channels in each country.Periods shown are rolling 12 months to reduce volatility.Countries are assigned to Human Development Index categories and va
26、lues are indexed to rolling 12 months to March 2013 to allow comparison.Start of pandemicVery highHDIHighHDIMediumHDILowHDI250200150100500Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023300250200150100500Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
27、Mar 2020Mar 2021Mar 2022Mar 2023Start of pandemic?Adult vaccine spendingADULT VACCINATION EXPENDITURE IS A LOW PROPORTION OF OVERALL PHARMACEUTICAL EXPENDITURE AND VARIES SUBSTANTIALLY ACROSS COUNTRIES AND REGIONS Spend on adult vaccines represents a minor share of the wider pharmaceutical expenditu
28、re on drugs and?adult vaccine spend only amounts to less than 2%of total pharmaceutical expenditure.Over time,there has been?in other countries and regions,the proportion is much?This suggests that that there may be a greater need for focus and potential investment in adult vaccination,particularly
29、in developing countries that are witnessing the fastest increase in adult populations.?Source:IQVIA MIDAS?coverage for children and mothers)?of 1mL or larger were assumed for adult use.Includes retail and non-retail from 76 countries covered by IQVIA MIDAS panels.These may not cover all vaccination
30、delivery channels in each country.?Source:IQVIA MIDAS?Children 6 months through 17 years,United States);UK Government(Vaccination coverage for children and mothers)?diphtheria,tetanus and pertussis(TDaP);hepatitis B;herpes zoster and pneumococcal.Diphtheria,tetanus and pertussis vaccinations in comb
31、ination?with available adult and pediatric coverage(UK and US).Only hepatitis B doses of 1mL or larger were assumed for adult use.Data period is 12 months to March 2023.Comparison is made with all registered pharmaceutical sales,including retail and non-retail channels.These may not cover all vaccin
32、ation delivery channels in each country.The total pharmaceutical spend is captured through sales from the IQVIA MIDAS data panels(and extrapolated)of registered pharmaceutical products.These could be purchased out of pocket,reimbursed?Africa+MEAPACEuropeLATAMNorth America200019
33、2020202120221.0%1.0%1.0%0.9%1.0%1.1%1.1%1.3%1.3%1.1%0.3%0.4%0.1%0.2%0.4%0.3%0.1%0.2%0.4%0.3%0.1%0.2%0.4%0.3%0.1%0.2%0.4%0.4%0.1%0.2%0.4%0.4%0.1%0.2%0.4%0.4%0.1%0.2%0.5%0.6%0.1%0.2%0.4%0.6%0.1%0.2%0.4%0.7%0.1%0.2%0.8%0.3%0.1%0.3%0.4%0.7%1.2%1.4%1.7%SpainAustraliaUKFranceItalyJapanUSCanadaGermany6|Tre
34、nds in Global Adult Vaccination:Impact of COVID-19?Older adults constitute a growing proportion of the?increasingly susceptible to infectious diseases due to age-related declines in immunity and live with a higher risk of comorbidities.Vaccination against common vaccine-preventable diseases has been
35、 shown to dramatically improve health and quality of life for adults around the world and,in some cases,reduce the risk of hospitalization by half and death by a third.21?of acute disease to avoiding long-term consequences such as resulting co-morbidities,ill health and reducing the incidence of chr
36、onic disease complications such as diabetes,respiratory illness,and heart failure,which can be costly.As such,adult immunization not only prevents diseases,hospitalizations and premature deaths,but also provides a wider individual and societal,economic?development target adults.22?antimicrobial resi
37、stance(AMR).Approximately 700,000 people die globally each year from AMR-related?10 million.23 Prevention of bacterial and viral infectious diseases through the use of vaccines can reduce the consumption of antibiotics and slow the level of AMR.24 This is a particularly crucial aspect of vaccines,as
38、 AMR can have large impacts on the health and economic well-being of a region.?they can relieve pressure on hospitals,physicians,and long-term care systems by preventing diseases,thereby?However,as demonstrated earlier,adult vaccination constitutes a minor share of overall pharmaceutical spending,es
39、pecially in less developed areas which have been witnessing the highest growth in adult populations.Additionally,any disruption to immunization services poses a threat to progress made to reduce the burden of VPDs,as was the case during the COVID-19 pandemic where 80-120 million vaccination doses fo
40、r adults in 2021 and 2022 are estimated to have been missed.Furthermore,disparities in vaccine uptake or access?economic classes across and within countries,but information on the extent of these disparities is limited.In fact,basic reporting on vaccination coverage for?adult vaccination should aim
41、to improve this reporting as this will allow for more evidence-based policy.The results shown in this research brief further highlight the need for continuous monitoring of adult vaccination rates.Additionally,while this research analyzes the missed doses in 2021 and 2022,further research on reasons
42、 behind this adverse impact is needed.Missed adult vaccinations during COVID-19 also need greater visibility and more in-depth analysis in terms of the impact to the system for direct health conditions such as shingles,?cardiovascular disease that increase with the prevalence?Although there is some
43、evidence of recovery in certain regions,adult immunization coverage was sub-optimal prior to COVID-19 and has seen further decline during the pandemic.There is an urgent need for action to ensure that the adult vaccination trajectory is further enhanced through continued prioritization and investmen
44、ts to chart a new course for healthier,more resilient societies across the globe.COVID-19 reinforced the power of immunization and demonstrated that high uptake can be achieved in adults.This momentum should be maintained to strengthen the public health value of vaccination.iqviainstitute.org|7With
45、new adult vaccines becoming available which aim to address unmet medical needs and avoid unnecessary healthcare spending,increasing adult immunization coverage and enhancing policies that optimize ease of access will be crucial.The following approaches may support optimization of adult vaccination g
46、lobally and capitalize on the substantial progress made during COVID-19 to raise awareness of adult vaccination and deploy policies to realize high vaccine uptake:Make adult immunization a standard of care,including prioritization of timely national immunization?as science and new technologies addre
47、ss unmet medical need(e.g.,RSV).Ensure adequate funding to implement equitable and accessible vaccination programs with a greater emphasis on prevention.Operationalize the adult vaccination calendar by improving clarity and simplifying timing of receiving vaccines over the year to limit missed oppor
48、tunities.?,expanding beyond doctors and medical clinics(e.g,pharmacists),creating additional access points to improve health equity.As demonstrated by the COVID-19 pandemic,ease of access and convenience plays an important role to reach the adult population equitably,and pharmacists are instrumental
49、 providers.?Laws and regulations that ease the ability of pharmacists to immunize patients are important for ensuring that they continue to provide access to a broad set of vaccines.Capture and report vaccination data to track progress and enable follow-up.Capture and analyze data for prioritization
50、 and allocation of funding and improve digital data availability infrastructure nationally and regionally.Track the completion?of vaccines.?to routinely and proactively initiate vaccination conversations with patients,increase vaccine acceptance,and turn vaccines into vaccination.?on the consequence
51、s of infectious diseases and the value of adult immunization,including partnering with professional bodies.Highlight that adult vaccination is valuable for not only older adults but also society as a whole.Prevention should be communicated as a tool of positive impact for health systems and societie
52、s overall.8|Trends in Global Adult Vaccination:Impact of COVID-19?3.Islam,J.Y.,et al.Opportunities and Challenges of Adolescent and Adult Vaccination Administration Within?6.Vaccines Europe 2013.International Federation on Aging.Adult vaccination:a key component of healthy?(hospitalisations)%20per%2
53、0annum 11.WHO.A world in disorder.Global prepararedness monitoring board annual report 2020,2020.?12.Centers for Disease Control and Prevention.AdultVaxView Internet.Cdc.gov.2022 cited 2023 Jul 13.?13.Centers for Disease Control and Prevention.Vaccination coverage among adults in the United States,?
54、adults-2019-2020.htmlReferencesiqviainstitute.org|9?coverage-2022estimates.htm?16.Mathieu E,Ritchie H,Rods-Guirao L,Appel C,Giattino C,Hasell J,et al.Coronavirus Pandemic(COVID-19).?vaccinations?21.Doherty TM,Del Giudice G,Maggi S.Adult vaccination as part of a healthy lifestyle:moving from medical?
55、CONTACT US100 IMS Drive Parsippany,NJ 07054 United Statesinfoiqviainstitute.org iqviainstitute.org?The IQVIA Institute for Human Data Science is committed to using human data science to provide timely,fact-based perspectives on the dynamics of health systems and human health around the world.The cov
56、er artwork is a visual representation of this mission.Using algorithms and data from?the complexity,beauty and mathematics of human data science and the insights within the pages.The artwork on this research brief cover is based on the total doses of vaccines for adult populations dispensed globally between 2013 and 2022.